Regeneron (REGN) Offers Otarmeni Gene Therapy Free in U.S.
Published on Β· Source: cnbc.com
AI Summary
Summarized by AI from the source belowRegeneron Pharmaceuticals (REGN) announced its newly approved gene therapy, Otarmeni, will be offered for free in the U.S. while pricing in other countries is still undecided. CEO Leonard Schleifer indicated they are determining a fair price internationally. In clinical trials, 80% of participants saw hearing improvements, with estimates suggesting around 50 babies born annually in the U.S. with the condition. Analysts from Piper Sandler project peak sales of $130 million, emphasizing the limited financial impact due to the condition's rarity.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Regeneron Pharmaceuticals (REGN)
Regeneron is a biotechnology company known for Eylea and Dupixent.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier REGN news
REGN stock page and all news βGet the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
Related News
Aeromexico Plans New US Flights After Washington Lifts Restrictions
Oct 19
SpaceX AI Computing Power Rental Driving Revenue Growth but Raising Costs
Oct 19
A&W (TSX:AW) Q3 Results Show Margin Squeeze Impact
Oct 18
Aurum PropTech Focuses on Profits and Scale at Earnings Call
Oct 18